Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
|Dementia Alzheimers Disease|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Establishment of a Bank of Biospecimens for the Evaluation of New Methods Facilitating Early Diagnosis and the Monitoring of Progression and Therapy of Patients With Age-related Cognitive Disorders.|
- Tissue bank of biological specimens [ Time Frame: 5-10 years ]To establish a tissue bank of blood, urine and saliva from cognitively normal and cognitively impaired individuals 60 years or older to be used for the purpose of conducting research addressing: etiology, mechanism, diagnosis, and treatment of age-related cognitive disorders.
Biospecimen Retention: Samples With DNA
|Study Start Date:||July 2009|
|Study Completion Date:||March 2016|
|Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Patients in this cohort with be diagnosed with mild to moderate cognitive impairment, Alzheimers disease, Dementia, or any other form of cognitive impairment.
Patients in this cohort will be normal healthy adults over the age of 60 years that have no cognitive impairment.
Up to 1000 patients, with or without diagnosed cognitive disorders, are asked to participate by providing the investigators with blood, urine and saliva specimens to be stored in a Bio Bank for future research. Patients will be asked to participate on a yearly basis for up to 5 to 10 years by providing the investigators with the above-mentioned specimens, and also having a physical exam and having some cognitive testing performed at the initial visit and yearly visits.
Examples of the types of research are: new methods for improving the diagnosis and treatment of age-related cognitive disorders, new areas of biology, new areas of biotechnology, and possibly genetic research. If you do not want your specimens used for any specific type of research, you may specify that on the consent form.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00911690
|United States, Michigan|
|Royal Oak, Michigan, United States, 48073|
|Principal Investigator:||Khaled Imam, M.D.||Beaumont Hospitals|